Research Topics
| M Kelly NicholasSummaryAffiliation: University of Chicago Country: USA Publications
| Collaborators
|
Detail Information
Publications
Molecular heterogeneity in glioblastoma: therapeutic opportunities and challengesM Kelly Nicholas
Department of Neurology, University of Chicago, Chicago, IL 60637, USA
Semin Oncol 38:243-53. 2011..In this review, we discuss recent attempts to exploit new molecular insights, consider the reasons for slow progress in developing better treatments, and examine future therapeutic options...- Glioblastoma multiforme: evidence-based approach to therapyM Kelly Nicholas
University of Chicago, Department of Neurology, MC 2030, 5841 S Maryland Avenue, Chicago, IL 60637, USA
Expert Rev Anticancer Ther 7:S23-7. 2007..This review will focus on the current standard of care in the USA for newly diagnosed GBM, focusing on the evidence supporting that care... 
Epidermal growth factor receptor - mediated signal transduction in the development and therapy of gliomasM Kelly Nicholas
Department of Neurology, University of Chicago, IL 60637, USA
Clin Cancer Res 12:7261-70. 2006..We will also consider the ways in which specific EGFR alterations common to glioma reflect outcomes following treatment with targeted therapies, all with an eye towards applying this understanding to improved patient outcomes...- Chemotherapy for malignant gliomaM Kelly Nicholas
Department of Neurology, University of Chicago, 5801 South Ellis Ave, Chicago, IL 60637, USA
Expert Rev Neurother 5:S41-9. 2005..This review will focus on medical therapies in the treatment of malignant glioma, never losing sight of their place as one of several therapeutic modalities used to confront brain cancer... - Emerging therapies for malignant gliomaRimas V Lukas
University of Chicago, Department of Neurology, MC 2030, 5841 S Maryland Avenue, Chicago, IL 60637, USA
Expert Rev Anticancer Ther 7:S29-36. 2007..Inhibitors of angiogenesis will also be discussed. Some 'targeted' therapies are less specific than others, working on more than one pathway or receptor, thus complex interactions are possible... - A phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomasJeffrey J Raizer
Department of Neurology, Northwestern University, Chicago, IL, USA
Cancer 116:5297-305. 2010..The authors evaluated a 3-week schedule of bevacizumab in patients with recurrent high-grade glioma (HGG)... 
A phase I study of continuous infusion cilengitide in patients with solid tumorsPeter H O'Donnell
Section of Hematology Oncology, Department of Medicine, The University of Chicago, 5841 S Maryland Ave, MC 2115, Chicago, IL 60637, USA
Invest New Drugs 30:604-10. 2012..However, cilengitide has a short half-life of 3-5 h with no evidence of drug accumulation. These data prompted the initiation of this phase I study of continuous infusion cilengitide...- A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium studyMichael D Prados
University of California, San Francisco, San Francisco, California 94143 0372, USA
Neuro Oncol 8:189-93. 2006..52) for AG patients. Toxicity for the group included diarrhea and myelosuppression. We conclude that the recommended phase 2 dose of CPT-11 for patients with or without EIAED was ineffective on this schedule, in this patient population... - Dysregulation of PTEN and protein kinase B is associated with glioma histology and patient survivalRalph P Ermoian
Department of Radiation Oncology, The University of California, San Francisco 94143, USA
Clin Cancer Res 8:1100-6. 2002..11). CONCLUSIONS: Reduced PTEN expression is ubiquitous among GBM tumors and may play a role in the development of low-grade gliomas. PTEN inactivation in gliomas portends a particularly aggressive clinical behavior... - Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: A North American Brain Tumor Consortium studyVinay K Puduvalli
Department of Neuro Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 431, Houston TX 77030, USA
J Clin Oncol 22:4282-9. 2004..Fenretinide induces apoptosis in malignant gliomas in vitro. This two-stage phase II trial was conducted to determine the efficacy of fenretinide in adults with recurrent malignant gliomas... - Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiformeSusan M Chang
Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA, USA
Int J Radiat Oncol Biol Phys 60:353-7. 2004..It is unclear the added advantage thalid has in combination with TMZ for this patient population... - Permanent iodine 125 brachytherapy in patients with progressive or recurrent glioblastoma multiformeDavid A Larson
Department of Radiation Oncology, University of California San Francisco, San Francisco, CA 94143, USA
Neuro Oncol 6:119-26. 2004..We conclude that permanent 125I brachytherapy for recurrent or progressive GM is well tolerated. Survival time was comparable to that of a similar group of patients treated with temporary brachytherapy... - Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium studyMichael D Prados
Department of Neurological Surgery, University of California at San Francisco, San Francisco, CA 94143, USA
Neuro Oncol 6:44-54. 2004..A phase 2 study of patients with recurrent malignant glioma is ongoing to assess the efficacy of CPT-11 when the dose is stratified according to the use of EIAEDs... - Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium studyMichael D Prados
Department of Neurological Surgery, University of California at San Francisco, San Francisco, CA 94143, USA
Neuro Oncol 6:33-7. 2004..We conclude that BCNU plus temozolomide when used in these doses and schedule has only modest activity, with significant toxicity, and appears to be no more effective than single-agent temozolomide... - Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium studyKurt A Jaeckle
University of Texas M D Anderson Cancer Center, Houston, USA
J Clin Oncol 21:2305-11. 2003..This phase II trial evaluated efficacy and toxicity of combination temozolomide and cRA treatment in recurrent MG... - Melanoma chemoprevention: a role for statins or fibrates?Robert P Dellavalle
Department of Dermatology, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
Am J Ther 10:203-10. 2003..This article reviews melanoma biology and the clinical evidence for the use of lipid-lowering medications for melanoma chemoprevention and/or adjuvant chemotherapy... - Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiformeYu Liang
Preuss Laboratory for Molecular Neuro oncology and Department of Neurological Surgery, University of California San Francisco, San Francisco, CA 94143, USA
Proc Natl Acad Sci U S A 102:5814-9. 2005..Our analyses thus identify and validate a prognostic marker of both biologic and clinical significance and provide a series of putative markers for additional evaluation...